Cancer antigen, cancer therapy, and cancer diagnosis

Claim 2

Antisera and antibodies with specificity against a human cancer cell associated α-neuramino glycoprotein having inhibitory activity upon C1 esterase hydrolyzing effect, and inhibitory effect on C1 activation of C4 as shown by the inhibition of complement haemolysis.

Claim 3

A process for preparing the antisera claimed in claim 1, comprising immunizing non-human host animals with a human cancer cell associated α-neuramino glycoprotein having the properties stated in claim 1, and harvesting serum from the immunized animal.

Claim 4

A human cancer cell associated protein, termed C1 IAC, said protein being an α-neuramino glycoprotein showing the following characteristics: (1) inhibitory activity on C1 esterase hydrolyzing effect; (2) inhibitory effect on C1 activation of C4 as shown by the inhibition of complement haemolysis; (3) lack of effect upon the clotting time of plasma; (4) inhibitory effect on fibrinolysis; (5) inhibitory effect against the plasma fibrinolytic system as demonstrated by fibrin agarose electrophoresis; (6) progressive loss of inhibitory activity on C1 esterase hydrolyzing effect below pH 5.5 and above pH to 10.5; (7) loss of inhibitory activity on C1 esterase hydrolyzing effect upon incubation at temperatures exceeding 56° C. for 30 minutes; (8) in Grabar-Scheidegger immunoelectrophoresis against rabbit antihuman C1 IA, a non- "gull wing" configurated precipitate which extends into the β zone when the immunoelectrophoresis is run in the presence of calcium lactate; (9) immunoelectrophoretical identity with C1 IA in tandem-crossed immunoelectrophoresis in gel containing rabbit antihuman C1 IA; (10) loss of ability to precipitate with rabbit antihuman C1 IA upon treatment with neuraminidase; (11) in Ouchterlony immunodiffusion, yielding a precipitate different from the C1 IA precipitate against antiserum from host animals which are able to distinguish between C1 IA and C1 IAC, such as from pigs of Danish "Landrace"; (12) a molecular weight of 110,000-130,000, when estimated by the gel filtration technique; (13) a sedimentation constant s° 20 ,w of 6.2 S.

Claim 5

A human cancer cell associated protein, termed C1 IAC, said protein being an α-neuramino glycoprotein showing the following characteristics: (1) inhibitory activity on C1 esterase hydrolyzing effect; (2) inhibitory effect on C1 activation of C4 as shown by the inhibition of complement haemolysis; (3) lack of effect upon the clotting time of plasma; (4) inhibitory effect on fibrinolysis; (5) inhibitory effect against the plasma fibrinolytic system as demonstrated by fibrin agarose electrophoresis; (6) progressive loss of inhibitory activity on C1 esterase hydrolyzing effect below pH 5.5 and above pH to 10.5; (7) loss of inhibitory activity on C1 esterase hydrolyzing effect upon incubation at temperatures exceeding 56° C. for 30 minutes; (8) in Grabar-Scheidegger immunoelectrophoresis against rabbit antihuman C1 IA, a non- "gull wing" configurated precipitate which extends into the β zone when the immunoelectrophoresis is run in the presence of calcium lactate; (9) immunoelectrophoretical identity with C1 IA in tandem-crossed immunoelectrophoresis in gel containing rabbit antihuman C1 IA; (10) loss of ability to precipitate with rabbit antihuman C1 IA upon treatment with neuraminidase; (11) in Ouchterlony immunodiffusion, yielding a precipitate different from the C1 IA precipitate against antiserum from host animals which are able to distinguish between C1 IA and C1 IAC, such as from pigs of Danish "Landrace"; (12) a molecular weight of 110,000-130,000, when estimated by the gel filtration technique; (13) a sedimentation constant s° 20 ,w of 6.2 S.

Claim 6

A protein, termed C1 IAC, according to claim 3, in substantially pure form.

Claim 9

Antisera, antibodies, antibody fragments, antibody modifications, and antibody derivatives with specificity against C1 IAC.

Claim 10

Antisera, antibodies, antibody fragments, antibody modifications, and antibody derivatives with specificity against C1 IAC.

Claim 11

Antisera and antibodies according to claim 6, comprising substantially pure pig IgG immunoglobulins.

Claim 12

Antisera and antibodies according to claim 6, labelled with a radioactive isotope.

Claim 13

Antisera and antibodies according to claim 6, chemically bound to a cytostatic.

Claim 14

Matrix-immobilized antisera and antibodies reactive with C1 IAC.

Claim 15

Matrix-immobilized antisera and antibodies reactive with C1 IAC.

Claim 18

A reagent comprising anti C1 IAC.

Claim 19

A reagent comprising anti C1 IAC.

Claim 20

A diagnostic kit comprising anti C1 IAC incorporated in a gel layer, said gel layer being disposed on a support; and a container therefor.

Claim 21

A diagnostic kit comprising anti C1 IAC incorporated in a gel layer, said gel layer being disposed on a support; and a container therefor.

Claim 22

A diagnostic kit according to claim 13, wherein the gel is an agarose gel.

Claim 23

A diagnostic kit according to claim 14, wherein the agarose gel layer is provided with holes adapted for use in radial immuno-diffusion techniques.